




Anti-post-translational modification polyclonal antibodies



Services

From STANDARD
to ALL INCLUSIVE
service

Custom projects

Protocols
adapted to your
requirements

Technical support

Advice from
experts in
immunology

Ethics

Approved
Health & Safety
procedures

IMMUNOGEN

Based on the following information on the target protein and the antibody to be developed:



We perform the design, synthesis and conjugation of a specific and immunogenic modified peptide to be injected.

DESIGN

We use specific software and in-house expertise to design the most relevant peptide. The sequence is chosen to make sure that the immune response is optimal against the expected modification, based on:

- the immunogenicity of the flanking sequences of aminoacids,
- the presence of conserved patterns according to your constraints of cross-reactivity.

You receive:

HAWTGGSEHFSSSL



The most relevant peptide sequence to be validated.

SYNTHESIS

Peptides are synthesised using solid phase Fmoc chemistry, and analysed by HPLC and mass spectrometry.

1 modified peptide

up to 15 residues
20 to 25 mg

1 unmodified control peptide

Same sequence
5 to 10 mg

You receive:



All remaining peptide(s) after immunisation.




A technical data sheet including HPLC and mass spectrometry profiles for each peptide.

CONJUGATION

Conjugation is usually carried out on a cysteine residue (which can be added to the N- or C-terminus of the peptide if required), but several other methods can be used.


Peptides are conjugated to one of the following carrier proteins:



5 mg of the modified peptide are conjugated to the carrier protein for the immunisation step.

IMMUNISATION PROTOCOL

Animals are immunised⁽¹⁾ with the modified peptide according to specifically optimised protocols.



At the end of the immunisation protocol, you can:

✓ **terminate** the protocol and request the final bleed.

↻ **extend** the protocol and request:

- additional injections and / or
- additional test bleeds


⁽¹⁾ All experiments are carried out by authorised staff and established according to the French legislation governing the use of animals in experiments. Our animal house is registered under the reference No C21 464 04 EA.

ADDITIONAL SERVICES

ELISA MONITORING

For every sample we take during the immunisation protocol, the sera immunoreactivity is measured using an ELISA against **both modified and control peptides** coated to the wells of a microtitre plate.

The comparison between the results obtained for the modified peptide and those obtained for the control peptide allows us to check that the antibodies are specific for the modification.




Example of the evolution of a serum immunoreactivity against a post-translationally modified peptide and the corresponding unmodified control peptide during an immunisation protocol

You receive:

The ELISA results, showing the **serum immunoreactivity against both peptides**, as well as its evolution over the protocol. Alongside with **the results of your own tests, our expertise and our advice**, you are able at each step to make the right decision whether to continue the project or not.

PEPTIDE AFFINITY PURIFICATION

Anti-PTM polyclonal antibody development projects include the immunopurification of up to **5 mL of the final immune serum** according to a 3-step procedure in order to discard antibodies that are specific for the control peptide:



You receive:



Your purified antibodies in a glycine buffer⁽²⁾.



A data report showing the conditions and results of the purification.

(2) Glycine 0.1 M, Tris 0.1 M pH7.8, sodium azide 0.02%. If you do not wish azide to be added, please let us know on your order.

